HAE
Haemonetics Corporation
Healthcare · Medical - Instruments & Supplies
Undervalued·Quality 85·RSI 39·DCF +902%·Conviction 85
Investment Thesis — Haemonetics Corporation
The market is mispricing Haemonetics as a legacy med-tech company, failing to fully account for its accelerating shift towards higher-growth, higher-margin segments like plasma collection and interventional cardiology. The current valuation implies a stagnant future, ignoring the compounding effect of its specialized, recurring revenue streams.
Catalysts
- Strong Q3/Q4 earnings beats driven by accelerating plasma and VASCADE revenue growth.
- Expansion of VASCADE's market share and new product indications in interventional cardiology.
- Analyst upgrades and increased price targets reflecting sustained margin expansion and growth.
Risk Factors
- Unexpected slowdown in global plasma collection volumes due to macroeconomic factors or regulatory changes.
- Intensified competition in the interventional cardiology or blood management segments.
- Supply chain disruptions impacting manufacturing or distribution of key products.
Key Debates
HAE's Fwd Rev Growth turns positive 2% by Q4 2024
Operating margins expand 100bps by H1 2025 despite negative growth
Analyst PT of $86.60 achieved by Q1 2025 on re-rating